Danone Recalls Ireland-Produced Infant Formula Batches While Oikos High-Protein Sales Rise Double-Digits
Danone reported double-digit growth in its Oikos Greek yogurt high-protein offerings as GLP-1 medication adoption accelerated consumer demand. It announced a targeted recall of specific infant formula batches produced in Ireland, withdrawing limited product lots from select markets under updated authorities’ guidance.
1. Danone Leverages Protein-Driven Market Growth
Danone has reported a surge in demand for its high-protein yogurt offerings, driven in part by the growing adoption of GLP-1 weight-loss medications. The company’s Oikos Greek yogurt line posted double-digit volume growth in the fourth quarter of 2025 compared with the prior year, outpacing the overall Greek yogurt segment, which grew mid-single digits. Danone’s research indicates that 70% of American consumers now prioritize higher protein intake, and the company is expanding production of dairy-based protein isolates to supply both its own brands and third-party food manufacturers.
2. Premium Pricing Boosts Revenue Potential
Market research from Circana shows that food and beverage products labeled as high-protein command price premiums of up to 12%. Danone has capitalized on this trend by reformulating key SKUs across its Essential Dairy & Plant-Based portfolio. Ready-to-drink protein shakes, a fast-growing category, reached $8.1 billion in U.S. sales in 2025—up 71% over four years—and Danone expects its new protein-fortified drink launches to capture a meaningful share of this expanding market.
3. Targeted Recall of Infant Formula Batches
On January 23, 2026, Danone initiated a targeted recall of specific infant formula batches produced in Ireland in response to evolving guidance from local food authorities. The recall affects a limited number of SKUs distributed in select European and Middle Eastern markets. Danone emphasized that routine quality controls and additional analyses confirmed the safety and compliance of its broader infant formula portfolio. Customer care lines have been established to handle inquiries, and the company is working with distributors to ensure rapid withdrawal of the affected batches.
4. Balance of Growth and Risk Management
Danone’s Renew strategy, aimed at restoring long-term growth and competitiveness, balances expansion in high-margin protein segments with rigorous safety protocols. While high-protein products present an attractive revenue stream, the recent recall underscores the importance of vigilant quality assurance. Danone’s global sales reached €27.4 billion in 2024, and management has reiterated its commitment to maintaining both growth momentum and consumer trust through transparent communication and ongoing investment in safety systems.